5740-35-2

Usage

InChI:InChI=1/C10H10O3S/c1-13-8-4-2-7(3-5-8)6-9(14)10(11)12/h2-6,14H,1H3,(H,11,12)

Upstream product

• 5462-97-5 5-(4-methoxybenzylidene)-2-thioxo-4-thiazolidinone 
• 123-11-5 4-methoxy-benzaldehyde 
• 1261158-91-1 (Z)-2-(5-(4-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
• 7647-01-0 hydrogenchloride 
• 141-84-4 2-thioxo-4-thiazolidinone 
• 55111-70-1 (5E,5Z)-5-(4-methoxybenzylidene)-3-phenyl-2-thioxo-1,3-thiazolidin-4-one 

Downstream Products

• 28030-16-2 3-(4-methoxyphenyl)-2-oxopropanoic acid 
• 94550-20-6 4,4'-dimethoxy-α,α'-disulfanediyl-di-cinnamic acid 
• 39938-85-7 α-benzylsulfanyl-4-methoxy-cinnamic acid 
• 861036-32-0 3-(4-methoxy-phenyl)-2-semicarbazono-propionic acid 
• 104484-28-8 5-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-6-oxo-5,6-dihydro-[1,4]oxathiine-2-carboxylic acid ethyl ester 
• 104484-32-4 (Z)-3-(4-Methoxy-phenyl)-2-(1-methyl-2-oxo-2-p-tolyl-ethylsulfanyl)-acrylic acid 
• 104484-11-9 (Z)-2-Acetylsulfanyl-3-(4-methoxy-phenyl)-acrylic acid 
• 104484-34-6 2-[(E)-1-Carboxy-2-(4-methoxy-phenyl)-vinylsulfanyl]-3-oxo-butyric acid ethyl ester 
• 104484-21-1 5-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-2-methyl-6-oxo-5,6-dihydro-[1,4]oxathiine-3-carboxylic acid ethyl ester 
• 104484-19-7 3-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-5-methyl-6-p-tolyl-[1,4]oxathiin-2-one 
• 104484-14-2 6-(4-Bromo-phenyl)-3-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-[1,4]oxathiin-2-one 
• 104484-39-1 6-(4-Bromo-phenyl)-3-[1-(4-methoxy-phenyl)-meth-(Z)-ylidene]-4-oxo-3,4-dihydro-4λ⁴-[1,4]oxathiin-2-one 
• 104484-41-5 5-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-2-methyl-4,6-dioxo-5,6-dihydro-4H-4λ⁴-[1,4]oxathiine-3-carboxylic acid ethyl ester 
• 104484-40-4 3-[1-(4-Methoxy-phenyl)-meth-(Z)-ylidene]-5-methyl-4-oxo-6-p-tolyl-3,4-dihydro-4λ⁴-[1,4]oxathiin-2-one 

Relevant academic research and scientific papers

Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases

Metallo-β-lactamases (MBLs) enable bacterial resistance to almost all classes of β-lactam antibiotics. We report studies on enethiol containing MBL inhibitors, which were prepared by rhodanine hydrolysis. The enethiols inhibit MBLs from different subclasses. Crystallographic analyses reveal that the enethiol sulphur displaces the di-Zn(II) ion bridging ‘hydrolytic’ water. In some, but not all, cases biophysical analyses provide evidence that rhodanine/enethiol inhibition involves formation of a ternary MBL enethiol rhodanine complex. The results demonstrate how low molecular weight active site Zn(II) chelating compounds can inhibit a range of clinically relevant MBLs and provide additional evidence for the potential of rhodanines to be hydrolysed to potent inhibitors of MBL protein fold and, maybe, other metallo-enzymes, perhaps contributing to the complex biological effects of rhodanines. The results imply that any medicinal chemistry studies employing rhodanines (and related scaffolds) as inhibitors should as a matter of course include testing of their hydrolysis products.

A novel hexanuclear silver(i) cluster containing a regular Ag6 ring with short Ag-Ag distances and an argentophilic interaction

The hexanuclear complex [HQ][Ag(p-mpspa)] (H2-p-mpspa = 3-(4-methoxyphenyl)-2-sulfanylpropenoic acid) was prepared by reacting the precursor [Ag(H-p-mpspa)] with diisopropylamine (Q). The complex was characterized by spectroscopic techniques and the structure was solved by a single crystal X-ray diffraction study. The crystal contains hydrogen-bonded diisopropylammonium cations and [Ag6(p-mpspa)6] 6- anions that are based on a regular Ag6 ring with each S-donor atom of the sulfanylcarboxylate ligand bridging two Ag atoms. The Ag-Ag bond distances, 2.8036(6) A, are very short and suggest a closed shell d10...d10 argentophilic interaction. To analyze the relative role of this interaction and that of the S-bridging atom the anionic [Ag6(p-mpspa)6]6- moiety has been studied theoretically at the Hartree-Fock (HF) and 2nd order Moller-Plesset perturbation theory (MP2) levels on a very simple [Ag 6(SH)6] A model system. A large model system [Ag 6(p-mpspa)6]6-B has also been studied by applying the ONIOM (QM/MM) approach using HF/UFF and MP2/UFF combinations as levels of theory. The six experimentally observed Ag(i)...Ag(i) supported interactions are reproduced when dispersion-type interactions are considered in the theory levels MP2 and ONIOM MP2/UFF for models A and B, respectively. The use of HF and ONIOM HF/UFF levels led to a similar hexanuclear structure but displayed a large hexagonal disposition without argentophilic contacts for both models A and B. The steric hindrance exerted by the ligands did not preclude the formation of argentophilic interactions, as observed experimentally.

Synthesis and antimicrobial activities of gold(I) sulfanylcarboxylates

Reaction of NaAuCl4H2O and thiodiglycol (1:3 molar ratio) with 3-(aryl)-2-sulfanylpropenoic acids, H2xspa0[x:p03-phenyl- , f03-(2-furyl)-, t03-(2-thienyl)-, o-py03-(2-pyridyl)-, Clp03-(2-chlorophenyl)- , -o-mp03- (2-methox

New structural features in triphenylphosphinesilver(I) sulfanylcarboxylates

We investigated the reactions of 1.5 : 1 : 1 mole ratio mixtures of triphenylphosphine, silver nitrate and 3-(aryl)-2-sulfanylpropenoic acids H 2xspa in chloroform/water, where in the acid nomenclature, spa = 2-sulfanylpropenoato and x = p, Clp